Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients

被引:24
作者
Moorman, AC
Von Bargen, JC
Palella, FJ
Holmberg, SD
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA
[2] Northwestern Univ, Sch Med, Chicago, IL USA
关键词
HIV; AIDS; opportunistic infection; Pneumocystis carinii pneumonia; breakthrough; prophylaxis;
D O I
10.1097/00042560-199810010-00013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Pneumocystis carinii pneumonia (PCP) remains the most frequently reported serious opportunistic infection in AIDS patients and the second highest cause of mortality among persons with AIDS in the United States, despite the availability of effective chemoprophylaxis. Methods: To evaluate incidence of PCP and determinants of PCP chemoprophylaxis failure, we analyzed data from 2842 patients visits to infectious diseases physicians at 10 HIV clinics (eight private and two public) in eight U.S, cities from January 1992 through June 1996 as part of the HIV Outpatient Study (HOPS). We performed a time-dependent regression analysis to examine potential determinants of PCP chemoprophylaxis failure. Results: The incidence of chemoprophylaxis failure was 4.6 PCP cases/100 person-years on chemoprophylaxis; these cases represent 67% of all incident episodes of PCP. In a multivariate analysis, the only significant predictors of chemoprophylaxis failure were the use of agents other than trimethoprim-sulfamethoxazole (TMP-SMX), history of prior PCP, and a CD4(+) T-lymphocyte cell count of <50 cells/mu l. Dosing or frequency of TMP-SMX did not seem to influence risk of chemoprophylaxis failure. Discussion: Chemoprophylaxis failure, especially among those with the most advanced immunosuppression or history of prior PCP, was the most significant source of new PCP cases in the HOPS cohort and thus represents one of the largest contributors to morbidity and mortality in this cohort.
引用
收藏
页码:182 / 188
页数:7
相关论文
共 20 条
  • [1] Beard CB, 1996, EMERG INFECT DIS, V2, P147
  • [2] CATT S, 1995, AIDS CARE, V7, P229, DOI 10.1080/09540129550126731
  • [3] *CDCP, 1997, HIV AIDS SURVEILLANC, V8, P18
  • [4] PERSISTENCE OF PNEUMOCYSTIS-CARINII IN PATIENTS WITH AIDS RECEIVING CHEMOPROPHYLAXIS
    EPSTEIN, LJ
    MEYER, RD
    ANTONSON, S
    STRIGLE, SM
    MOHSENIFAR, Z
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (05) : 1456 - 1459
  • [5] Freeman RC, 1996, AIDS EDUC PREV, V8, P58
  • [6] A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE OR AEROSOLIZED PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - AIDS CLINICAL-TRIALS GROUP PROTOCOL-021
    HARDY, WD
    FEINBERG, J
    FINKELSTEIN, DM
    POWER, ME
    HE, W
    KACZKA, C
    FRAME, PT
    HOLMES, M
    WASKIN, H
    FASS, RJ
    POWDERLY, WG
    STEIGBIGEL, RT
    ZUGER, A
    HOLZMAN, RS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (26) : 1842 - 1848
  • [7] Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177
  • [8] KAPLAN JE, 1997, 4 C RETR OPP INF WAS, P118
  • [9] KISSINGER P, 1995, J NATL MED ASSOC, V87, P19
  • [10] Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival
    Kitahata, MM
    Koepsell, TD
    Deyo, RA
    Maxwell, CL
    Dodge, WT
    Wagner, EH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (11) : 701 - 706